DELAND, Fla., April 3, 2018 Obstetrician and gynecologist Dr. Hussain Esmail Rawji recently performed the first Minerva ES procedure for heavy menstrual bleeding at AdventHealth DeLand.
Nearly 1 in 3 women suffer from excessive menstrual bleeding and find it difficult to work, exercise, or be socially active.
As the first new commercially available, FDA-approved product for heavy periods since 2001, the Minerva ES treatment can help women regain control of their lives.
In clinical studies for FDA approval, Minerva produced the highest ever result in rates: a 93 percent success rate (menstrual bleeding reduced to a normal level or less) and 72 percent amenorrhea rate (zero bleeding).
This simple, one-time procedure takes just over three minutes and can be performed as an outpatient procedure with minimal anesthesia. After treatment, patients experience rapid recovery.
Minerva works without the use of implants or hormones. Instead, this procedure treats the tissue lining of the uterus (called the endometrium) with heat. This tissue is the source of heavy bleeding in women who have not reached menopause.
Minerva ES is only indicated for pre-menopausal women for whom childbearing is complete, and are suffering from excessive menstrual bleeding due to benign causes.
About AdventHealth DeLand
AdventHealth DeLand is a member of Adventist Health System, a faith-based health care organization with 45 hospital campuses and 8,200 licensed beds in nine states, serving more than 5 million patients annually. With a mission to extend the healing ministry of Christ, AdventHealth DeLand has 164-beds and is one of the seven AdventHealths in Flagler, Lake and Volusia counties that composes the AdventHealth Central Florida Division - North Region. As the largest hospital system in the area, the AdventHealth Central Florida Division - North Region has 1,226 beds and more than 7,800 employees.
About Minerva Surgical, Inc.
Minerva Surgical, Inc., founded in 2008, is a private medical technology company based in Redwood City, CA. The company's efforts are focused on delivering next-generation products for women's healthcare.